PMID- 15814163
OWN - NLM
STAT- MEDLINE
DCOM- 20050802
LR  - 20220409
IS  - 0167-4943 (Print)
IS  - 0167-4943 (Linking)
VI  - 40
IP  - 3
DP  - 2005 May-Jun
TI  - Interleukin-18 (IL-18) and matrix metalloproteinase-9 (MMP-9) in post-menopausal 
      osteoporosis.
PG  - 299-305
AB  - This survey covered 60 post-menopausal women with osteoporosis. The patients were 
      divided into three equal groups, and each group was treated with one of the three 
      so-called anti-resorptive drugs, namely alendronate (10 mg/day) risedronate (5 
      mg/day) and raloxifene (60 mg/day) for 12 months. The Elisa technique was used to 
      measure circulating IL-18 and MMP-9. Lumbar bone mineral density (BMD) levels 
      were determined by using dexa mineralometry (Lunar DPX) at baseline and after 12 
      months of treatment. The results showed comparable responses of the patients 
      treated with alendronate or risedronate, being a significant increase in BMD, an 
      increase in circulating IL-18, and only slight modifications in circulating MMP-9 
      levels. After 12 months of treatment with raloxifene, there were minimal, 
      non-significant increases in BMD, slight modifications in IL-18 levels, and a 
      significant reduction in circulating MMP-9 levels. The conclusions can be drawn 
      that all three drugs, albeit through different mechanisms, can be considered 
      valid treatments for post-menopausal osteoporosis. Although measurements of 
      circulating IL-8 and MMP-9 levels allowed us to differentiate the effects of the 
      three drugs used, as of today, they have no real role in the diagnosis and/or 
      follow-up of osteoporosis.
FAU - Maugeri, D
AU  - Maugeri D
AD  - Department of Senescent, Urological and Neurourological Sciences, University of 
      Catania, Cannizzaro Hospital, Via Messina, 829, I-95126 Catania, Italy. 
      dmaugeri@tin.it
FAU - Mamazza, C
AU  - Mamazza C
FAU - Lo Giudice, F
AU  - Lo Giudice F
FAU - Puglisi, N
AU  - Puglisi N
FAU - Muscoso, E G
AU  - Muscoso EG
FAU - Rizzotto, M
AU  - Rizzotto M
FAU - Testai, M
AU  - Testai M
FAU - Bennati, E
AU  - Bennati E
FAU - Lentini, A
AU  - Lentini A
FAU - Panebianco, P
AU  - Panebianco P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20041201
PL  - Netherlands
TA  - Arch Gerontol Geriatr
JT  - Archives of gerontology and geriatrics
JID - 8214379
RN  - 0 (Interleukin-18)
RN  - 0 (Selective Estrogen Receptor Modulators)
RN  - 4F86W47BR6 (Raloxifene Hydrochloride)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - KM2Z91756Z (Risedronic Acid)
RN  - M2F465ROXU (Etidronic Acid)
RN  - X1J18R4W8P (Alendronate)
SB  - IM
MH  - Alendronate/*therapeutic use
MH  - Bone Density/*drug effects
MH  - Etidronic Acid/*analogs & derivatives/*therapeutic use
MH  - Female
MH  - Humans
MH  - Interleukin-18/*blood
MH  - Matrix Metalloproteinase 9/*blood
MH  - Middle Aged
MH  - Osteoporosis, Postmenopausal/*drug therapy
MH  - Raloxifene Hydrochloride/*therapeutic use
MH  - Risedronic Acid
MH  - Selective Estrogen Receptor Modulators/*therapeutic use
EDAT- 2005/04/09 09:00
MHDA- 2005/08/03 09:00
CRDT- 2005/04/09 09:00
PHST- 2004/06/30 00:00 [received]
PHST- 2004/10/03 00:00 [revised]
PHST- 2004/10/04 00:00 [accepted]
PHST- 2005/04/09 09:00 [pubmed]
PHST- 2005/08/03 09:00 [medline]
PHST- 2005/04/09 09:00 [entrez]
AID - S0167-4943(04)00172-4 [pii]
AID - 10.1016/j.archger.2004.10.001 [doi]
PST - ppublish
SO  - Arch Gerontol Geriatr. 2005 May-Jun;40(3):299-305. doi: 
      10.1016/j.archger.2004.10.001. Epub 2004 Dec 1.